Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Refractory Inflammatory Bowel Disease.

Thomas A. Judge1, Gary R. Lichtenstein

  • 1Division of Gastroenterology, Department of Medicine, Hospital of the University of Pennsylvania, University of Pennsylvania School of Medicine, Ravdin Building, 3rd Floor, 3400 Spruce Street, Philadelphia, PA 19104-4283, USA. grl@mail.med.upenn.edu

Current Treatment Options in Gastroenterology
|July 27, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Refractory Inflammatory Bowel Disease.

Current treatment options in gastroenterology·2004
Same author

The role of biological therapy in inflammatory bowel disease.

Drugs of today (Barcelona, Spain : 1998)·2003
Same journal

Esophageal Disorders in the Older Adult.

Current treatment options in gastroenterology·2025
Same journal

Endobariatrics: a Still Underutilized Weight Loss Tool.

Current treatment options in gastroenterology·2023
Same journal

Management of Post Ablative Barrett's Esophagus: a Review of Current Practices and Look at Emerging Technologies.

Current treatment options in gastroenterology·2023
Same journal

Inflammatory Bowel Disease Therapy and Venous Thromboembolism.

Current treatment options in gastroenterology·2023
Same journal

Ileal Pouch-Anal Anastomosis in the Older Adult: a Review of Postoperative Outcomes and Pouchitis Treatment.

Current treatment options in gastroenterology·2023
Same journal

Celiac Disease in the Elderly.

Current treatment options in gastroenterology·2023
See all related articles

Biologic therapies offer new options for refractory ulcerative colitis and Crohn's disease. Standard treatments include corticosteroids and cyclosporine A, while biologics like anti-TNF-alpha agents are effective for severe cases.

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • Refractory colonic inflammation in ulcerative colitis (UC) and Crohn's disease (CD) presents significant treatment challenges.
  • Traditional therapies like intravenous corticosteroids and cyclosporine A are mainstays for severe UC.
  • The advent of biologic therapies has expanded therapeutic strategies for inflammatory bowel diseases.

Purpose of the Study:

  • To review current and emerging therapeutic options for refractory colonic inflammation in UC and CD.
  • To highlight the efficacy of biologic agents and immunomodulatory therapies.
  • To outline indications for surgical intervention in severe cases.

Main Methods:

  • Review of established and novel therapeutic modalities for UC and CD.

Related Experiment Videos

  • Analysis of the role of biologic agents targeting tumor necrosis factor alfa (TNF-alpha).
  • Evaluation of immunomodulatory agents such as azathioprine, 6-mercaptopurine, and methotrexate for maintenance of remission.

    • Main Results:

    • Biologic therapies have augmented treatment options for refractory colonic inflammation.
    • Anti-TNF-alpha monoclonal antibodies are highly efficacious in severe or refractory Crohn's disease.
    • Immunomodulatory therapies demonstrate efficacy in maintaining remission for both UC and CD.

    Conclusions:

    • Biologic agents represent a significant advancement in managing refractory inflammatory bowel disease.
    • A stepwise approach, incorporating biologics and immunomodulators, is crucial for optimizing patient outcomes.
    • Surgical intervention remains essential for medically refractory or complicated cases of severe colitis.